Recurrent Wnt medulloblastoma treated with marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue: a dual case report and review of the literature
- 4 May 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Child's Nervous System
- Vol. 38 (2), 465-472
- https://doi.org/10.1007/s00381-021-05197-6
Abstract
Wnt-activated medulloblastoma (MB) confers an excellent prognosis. However, specific treatment strategies for patients with relapsed Wnt-MB are unknown. We report two patients with recurrent beta-catenin nucleopositive Wnt-MB successfully treated by incorporating marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue (HDCx/AuHPCR). We also present a review of the literature for previously reported cases of relapsed Wnt-MB. We propose that patients with recurrent Wnt-MB may be treated using a multi-disciplinary approach that includes HDCx/AuHPCR with or without re-irradiation.This publication has 24 references indexed in Scilit:
- MedulloblastomaNature Reviews Disease Primers, 2019
- Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohortThe Lancet Oncology, 2018
- PDCT-09. TEMOZOLOMIDE WITH IRINOTECAN VERSUS TEMOZOLOMIDE, IRINOTECAN PLUS BEVACIZUMAB FOR RECURRENT MEDULLOBLASTOMA/CNS PNET OF CHILDHOOD: REPORT OF A COG RANDOMIZED PHASE II SCREENING TRIALNeuro-Oncology, 2017
- Intertumoral Heterogeneity within Medulloblastoma SubgroupsCancer Cell, 2017
- Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 studyJournal of Neuro-Oncology, 2016
- MB-109PRELIMINARY RESULTS OF COG ACNS0331: A PHASE III TRIAL OF INVOLVED FIELD RADIOTHERAPY (IFRT) AND LOW DOSE CRANIOSPINAL IRRADIATION (LD-CSI) WITH CHEMOTHERAPY IN AVERAGE RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUPNeuro-Oncology, 2016
- Feasibility of an Attenuated Maintenance Chemotherapy Regimen Directed at Adolescents and Young Adults with Newly Diagnosed Localized Medulloblastoma and Other Central Nervous System Embryonal TumorsJournal of Adolescent and Young Adult Oncology, 2014
- Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysisThe Lancet Oncology, 2013
- Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-AnalysisJournal of Clinical Oncology, 2010
- Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trialThe Lancet Oncology, 2006